Literature DB >> 15689955

Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability.

Svetlana M Stamatovic1, Parvin Shakui, Richard F Keep, Bethany B Moore, Steven L Kunkel, Nico Van Rooijen, Anuska V Andjelkovic.   

Abstract

The present study was designed to elucidate the effects of the chemokine monocyte chemoattractant protein (MCP-1) on blood-brain barrier (BBB) permeability. Experiments were conducted under in vitro conditions (coculture of brain endothelial cells and astrocytes) to study the cellular effects of MCP-1 and under in vivo conditions (intracerebral and intracerebroventricular administration of MCP-1) to study the potential contribution of MCP-1 to BBB disruption in vivo. Our results showed that MCP-1 induces a significant increase in the BBB permeability surface area product for fluorescein isothiocyanate (FITC)-albumin under in vivo conditions, particularly during prolonged (3 or 7 days) exposure (0.096+/-0.008 versus 0.031+/-0.005 microL/g min in controls at 3 days, P<0.001). Monocyte chemoattractant protein-1 also enhanced (17-fold compared with control) the permeability of the in vitro BBB (coculture) model. At the cellular level, MCP-1 causes alteration of tight junction (TJ) proteins in endothelial cells (redistribution of TJ proteins determined by Western blotting and loss of immunostaining for occludin, claudin-5, ZO-1, ZO-2). Monocyte chemoattractant protein-1-induced alterations in BBB permeability are mostly realized through the CCR2 receptor. Absence of CCR2 diminishes any effect of MCP-1 on BBB permeability in vitro and in vivo. The permeability surface area product for FITC-albumin after 3 days exposure to MCP-1 was 0.096+/-0.006 and 0.032+/-0.007 microL/g min, in CCR2+/+ and CCR2-/- mice, respectively (P<0.001). Monocytes/macrophages also participate in MCP-1-induced alterations in BBB permeability in vivo. Monocytes/macrophages depletion (by clodronate liposomes) reduced the effect of MCP-1 on BBB permeability in vivo approximately 2 fold. Our results suggest that, besides its main function of recruiting leukocytes at sites of inflammation, MCP-1 also plays a role in 'opening' the BBB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15689955     DOI: 10.1038/sj.jcbfm.9600055

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  168 in total

1.  Kyotorphin transport and metabolism in rat and mouse neonatal astrocytes.

Authors:  Jianming Xiang; Huidi Jiang; Yongjun Hu; David E Smith; Richard F Keep
Journal:  Brain Res       Date:  2010-06-09       Impact factor: 3.252

2.  Acute mountain sickness, inflammation, and permeability: new insights from a blood biomarker study.

Authors:  Colleen Glyde Julian; Andrew W Subudhi; Megan J Wilson; Andrew C Dimmen; Travis Pecha; Robert C Roach
Journal:  J Appl Physiol (1985)       Date:  2011-06-02

3.  Blood-brain barrier pathophysiology in traumatic brain injury.

Authors:  Adam Chodobski; Brian J Zink; Joanna Szmydynger-Chodobska
Journal:  Transl Stroke Res       Date:  2011-12       Impact factor: 6.829

4.  Vasopressin amplifies the production of proinflammatory mediators in traumatic brain injury.

Authors:  Joanna Szmydynger-Chodobska; Leora M Fox; Kirsten M Lynch; Brian J Zink; Adam Chodobski
Journal:  J Neurotrauma       Date:  2010-08       Impact factor: 5.269

Review 5.  Myeloid Cells in the Central Nervous System.

Authors:  Jasmin Herz; Anthony J Filiano; Ashtyn Smith; Nir Yogev; Jonathan Kipnis
Journal:  Immunity       Date:  2017-06-20       Impact factor: 31.745

6.  Chemokines and their receptors in intracerebral hemorrhage.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Transl Stroke Res       Date:  2012-04-03       Impact factor: 6.829

Review 7.  Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke.

Authors:  Sajad Sarvari; Faezeh Moakedi; Emily Hone; James W Simpkins; Xuefang Ren
Journal:  Metab Brain Dis       Date:  2020-04-15       Impact factor: 3.584

8.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

9.  The prostaglandin E2 receptor EP3 controls CC-chemokine ligand 2-mediated neuropathic pain induced by mechanical nerve damage.

Authors:  Elsa-Marie Treutlein; Katharina Kern; Andreas Weigert; Neda Tarighi; Claus-Dieter Schuh; Rolf M Nüsing; Yannick Schreiber; Nerea Ferreirós; Bernhard Brüne; Gerd Geisslinger; Sandra Pierre; Klaus Scholich
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

10.  Non-muscle Mlck is required for β-catenin- and FoxO1-dependent downregulation of Cldn5 in IL-1β-mediated barrier dysfunction in brain endothelial cells.

Authors:  Richard S Beard; Ricci J Haines; Kevin Y Wu; Jason J Reynolds; Stephanie M Davis; John E Elliott; Nikolay L Malinin; Victor Chatterjee; Byeong J Cha; Mack H Wu; Sarah Y Yuan
Journal:  J Cell Sci       Date:  2014-02-12       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.